



Diverse Bacteriocins Produced by Strains From the Human Milk Microbiota

Angeliki Angelopoulou^{1,2}, Alicja K. Warda², Paula M. O'Connor^{2,3},
Stephen R. Stockdale², Andrey N. Shkoporov², Des Field^{1,2}, Lorraine A. Draper²,
Catherine Stanton^{2,3}, Colin Hill^{1,2} and R. Paul Ross^{1,2,3*}

¹ School of Microbiology, University College Cork, Cork, Ireland, ² APC Microbiome Ireland, University College Cork, Cork, Ireland, ³ Teagasc Food Research Centre, Moorepark, Fermoy, Ireland

OPEN ACCESS

Edited by:

Rustam Aminov,
University of Aberdeen,
United Kingdom

Reviewed by:

Takeshi Zendo,
Kyushu University, Japan
Dzung B. Diep,
Norwegian University of Life Sciences,
Norway

Pablo E. Hernández,
Complutense University of Madrid,
Spain

*Correspondence:

R. Paul Ross
p.ross@ucc.ie

Specialty section:

This article was submitted to
Antimicrobials, Resistance
and Chemotherapy,
a section of the journal
Frontiers in Microbiology

Received: 04 February 2020

Accepted: 02 April 2020

Published: 19 May 2020

Citation:

Angelopoulou A, Warda AK,
O'Connor PM, Stockdale SR,
Shkoporov AN, Field D, Draper LA,
Stanton C, Hill C and Ross RP (2020)
Diverse Bacteriocins Produced by
Strains From the Human Milk
Microbiota. *Front. Microbiol.* 11:788.
doi: 10.3389/fmicb.2020.00788

Microbial colonization of the infant gut is a convoluted process dependent on numerous contributing factors, including age, mode of delivery and diet among others that has lifelong implication for human health. Breast milk also contains a microbiome which acts as a source of colonizing bacteria for the infant. Here, we demonstrate that human milk harbors a wide diversity of bacteriocin-producing strains with the potential to compete among the developing gut microbiota of the infant. We screened 37 human milk samples and found isolates with antimicrobial activity and distinct cross-immunity profiles. From these isolates, we detected 73 putative gene clusters for bacteriocins of all known sub-classes, including 16 novel prepeptides. More specifically, we detected two novel lantibiotics, four sactibiotics and three class IIa bacteriocins with an unusual modification of the pediocin box that is composed of YDNGI instead of the highly conserved motif YGNGV. Moreover, we identified a novel class IIb bacteriocin, four novel class IIc and two class II d bacteriocins. In conclusion, human milk contains a variety of bacteriocin-producing strains which may provide them a competitive advantage in the colonization of the infant gut and suggests that the milk microbiota is a source of antimicrobial potential.

Keywords: human milk, bacteriocins, lantibiotics, sactibiotics, antimicrobials, genome mining, antibiotic resistance, human microbiota

INTRODUCTION

Human breast milk supplies the newborn with all essential nutrients required for growth (Martin et al., 2016). It also furnishes immunological benefits to the infant and acts as a gut-colonizing bacterial 'inoculum' for the infant's gastro-intestinal (GI) microbiota (Fernández et al., 2013). Human milk is a dynamic milieu that can alter in composition along the stages of lactation (Cabrera-Rubio et al., 2012). Previously, human milk was considered to be sterile, yet many recent studies have provided evidence to the contrary (Heikkilä and Saris, 2003; Collado et al., 2009; Hunt et al., 2011; Mediano et al., 2017). The exact mechanisms of bacterial colonization of milk have yet to be fully elucidated. The skin, the infant oral cavity and even the partner's microbes are potential sources of bacteria for human milk (Hunt et al., 2011; Kort et al., 2014; Biagi et al., 2017; Ross et al., 2017). Moreover, bacteria of the maternal GI microbiota can spread to the mammary gland through the entero-mammary pathway (Perez et al., 2007).

While international and national health organizations promote exclusive breastfeeding for the first six months of life (WHO, 2000; Abou-Dakn et al., 2010), this may not always be feasible

for a variety of reasons (Li et al., 2008). Mastitis is an inflammation of breast tissue and is a common disease that can affect up to 33% of women, often culminating in the discontinuation of breastfeeding (Jiménez et al., 2008; Civardi et al., 2013). Moreover, we have recently found that the incidence of subclinical mastitis could be as high as 38% (Angelopoulou et al., 2020). Major etiological agents of mastitis include *Staphylococcus aureus*, *Staphylococcus epidermidis*, and members of *Corynebacteriales*. The main standard treatment for the infection is antibiotics (Angelopoulou et al., 2018) although scientists are endeavoring to search for alternative therapies such as bacteriocins (Fernández et al., 2008). These are ribosomally synthesized antimicrobial peptides produced by bacteria that have either broad or narrow range inhibition spectra (Cotter et al., 2013). Bacteriocin producing microbes can be identified via traditional plating methods (O'Sullivan et al., 2019), and more recently through metagenomic *in silico* predictions, using programs such as BAGEL and antiSMASH (Collins et al., 2017; Egan et al., 2018).

Bacteriocins produced by Gram positive bacteria are grouped in two classes, namely class I and class II (Kotelnikova and Gelfand, 2002). The class II bacteriocins may be further subdivided in the pediocin-like (class IIa) bacteriocins, the two-peptide (class IIb) bacteriocins, the cyclic (class IIc) bacteriocins, and the linear, non-pediocin-like (class IId) bacteriocins (Cotter et al., 2005, 2013). Additional bacteriocin subgroups have been also suggested. To date, two class I bacteriocins, lacticin 3147 (Crispie et al., 2005; Klostermann et al., 2009) and nisin (Angelopoulou et al., 2018) have been suggested as alternative treatments for bovine and human mastitis, respectively. They are believed to act as a first line of defense, protecting the host against pathogen invasion (Chikindas et al., 2018). Bacteriocin-producer organisms can impede pathogens from becoming established in a niche by preventing biofilm formation via inhibition of quorum sensing with low level production of bacteriocins (Algburi et al., 2017).

The present study aimed to screen 37 asymptomatic human milk samples for bacteria that produce bacteriocins that target mastitic pathogens with the ultimate aim to identify novel bacteriocin clusters that could provide alternative therapeutic options to counter antibiotic resistance. This study presents discovery and analysis of 16 novel bacteriocin gene clusters.

MATERIALS AND METHODS

Detection and Isolation of Antimicrobial-Producing Human Milk Isolates

Thirty-seven asymptomatic lactating mothers were recruited through Cork University Maternity Hospital to donate breast milk, which was approved by the Cork Clinical Research Ethics Committee and the participants provided written informed consent. Approximately 10 mL aliquots of milk were collected aseptically using sterile gloves in a sterile tube with the first few drops (~500 µL) being discarded. The nipples and the mammary

areola had been cleaned with sterile alcohol-free aqueous solution moist wipes (Ted Kelleher, First Aid & Hygiene Supplies Ltd, Macroom, Ireland) in order to avoid contaminating the milk with skin-colonizing bacteria. Samples were stored below 4°C overnight until they were further processed. Aliquots of 1 mL of milk were cultivated within 24 h of donation. Aliquots of milk sample, 1 mL, were mixed with 9 mL of maximum recovery diluent (MRD; Oxoid, Basingstoke, United Kingdom) to make an initial 10⁻¹ dilution. Serial dilutions were enumerated by the spread plate method in duplicate onto: (a) Blood agar base (Oxoid, Basingstoke, United Kingdom) supplemented with 7% v/v defibrinated sheep blood (Cruinn Diagnostics, Dublin, Ireland) and incubated at 37°C for 48 h aerobically; which is a non-selective medium and (b) Baird Parker agar (Oxoid) supplemented with Egg Yolk Tellurite Emulsion (Oxoid) and incubated at 37°C for 48 h aerobically; which selects for staphylococci. Blood agar and Baird Parker plates with separate colonies were replicated in three clean Blood agar and Baird Parker plates, respectively using a replicator stamp (Karl Roth, Karlsruhe, Germany). Replicated plates were incubated at 37°C, aerobically for 48 h. The day after the 48 h incubation, plates were exposed to UV light for 45 min and then overlaid with Brain Heart Infusion (BHI) sloppy (Oxoid) containing 0.75% agar seeded with: (a) 0.25% of an overnight culture of *S. aureus* APC 3759 and grown aerobically overnight at 37°C; (b) 0.25% of an overnight culture of *M. luteus* DSM 1790 and grown aerobically overnight at 37°C and (c) 0.25% of an overnight culture of *P. aeruginosa* PA01 and grown aerobically overnight at 30°C. In total, 174 colonies exhibited antimicrobial activity against the tested strains and were grown overnight in BHI, streaked for purity and stocked in 40% glycerol in two 96-well plates which were stored at -80°C for further characterization.

Cross-Immunity

To determine the relatedness of the bacteriocins produced by the strains, cross-immunity assays were performed during which the producing strains were tested against each other by conducting spot bioassays using each producing strain as a producer and also as a target strain. More precisely, the two 96-well plates were stamped using a replica platter (Sigma-Aldrich, Germany) onto clean Tryptic Soy Agar (TSA) plates or Mueller Hinton (MH; Oxoid) plates; the plates were incubated aerobically overnight at 37°C, before UV irradiation for 45 min. These were then overlaid with the same media (0.75% w/v agar seeded with 0.25% of an overnight culture of the producing strains) and grown aerobically overnight. Cross-immunity was performed for each of the two 96-well plates separately. Strains with a distinct profile from the two 96-well plates were merged into one and cross-immunity was repeated as described-above leading to 80 strains with a distinct profile (**Supplementary Table S1**). The 80 strains were stored individually.

16S rRNA Sequencing

Colony PCR was performed on antimicrobial-producing strains with a distinct cross-immunity profile. Cells were lysed in 10% Igepal 630 (Sigma-Aldrich, Germany) at 95°C for 10 min. PCR was performed in a total volume of 25 µL using 10 µL of Phusion

Green Hot Start II High Fidelity PCR master mix (Thermo Fisher Scientific), 10 μ L of PCR-grade water, 1.5 μ L of the non-specific primers 27F and 1495R (primer stocks at 0.1 ng μ L⁻¹; Sigma-Aldrich) and 2 μ L of DNA template from lysed cells. Amplification was carried out with reaction conditions as follows: initial denaturation at 98°C for 30 s, followed by 35 cycles of 98°C for 10 s, annealing at 55°C for 30 s and elongation at 72°C for 30 s with a final extension step at 72°C for 10 min.

To confirm species, degenerate primers targeting the *dnaJ* gene (Shah et al., 2007) forward primer, 5'-GCCAAAAGA GACTATTATGA-3', and reverse primer, 5'-ATTGYTTACC YGTTTGTGTACC-3', were used for the PCR reactions, following conditions described by Shah et al. (2007).

Five microliters of the resulting amplicons from each reaction were electrophoresed in a 1.5% (w/v) agarose gel. A GeneGenius Imaging System (Syngene, Cambridge, United Kingdom) was used for visualization. The PCR products were purified using the GeneJet Gel Extraction Kit (Thermo Fischer Scientific, Waltham, MA, United States). DNA sequencing of the forward strand was performed by Source BioScience (Tramore, Ireland). The resulting sequences were used for searching sequences deposited in the GenBank database using BLAST¹ and the identity of the isolates was determined on the basis of the highest scores ($\geq 98\%$).

Spectrum of Inhibition

The spectrum of inhibition was completed on overnight cultures of 29 antimicrobial-producing isolates with a distinct immunity profile using 29 distinct indicator strains by a spot bioassay as described above with small modifications. More precisely, 5 μ L of an overnight culture of the 29 antimicrobial-producing isolates were spotted on a clean TSA plate and incubated aerobically overnight at 37°C, before UV irradiation for 45 min. The rest of the procedure was performed as described above. The indicator strains employed to detect antimicrobial activity and their optimal growth conditions are listed in **Table 1**. Anaerocult A gas packs (Merck, Darmstadt, Germany) were used to generate anaerobic conditions where necessary for a selection of the indicator strains used in the study. Zone size was measured as follows: diameter of zone – diameter of spot in millimeters. The experiment was performed in three independent replicates.

DNA Extraction and Sequencing

Genomic DNA was extracted from the 79 strains (with the exception of *S. lugdunensis* APC 3758) using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) with slight modifications. For Gram positive bacteria, 2 mL of an overnight culture (TSB; 1% inoculum) were centrifuged at 18,078 *g* for 10 min and the supernatant was discarded. The cell pellet was resuspended in 180 μ L of enzymatic lysis buffer and was incubated for 2 h at 37°C. The remaining steps were performed according to the original protocol. For the Gram-negative isolate *P. protegens* APC 3760, 2 mL of an overnight culture (TSB; 1% inoculum) were centrifuged at 18,078 *g* for 10 min and the supernatant was discarded. The cell pellet was resuspended in 180 μ L buffer ATL with the

remaining steps being performed according to the original protocol. Genomic DNA was quantified using a Qubit dsDNA HS Assay Kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA, United States). Apart from *S. lugdunensis* APC 3758, the remaining 79 strains were subjected to library preparation using the Nextera XT DNA Library Preparation Kit (Illumina, San Diego, CA, United States) and bead-based normalization following the standard manufacturer's protocol. Ready-to-load libraries were sequenced using a proprietary modified protocol using 2 \times 300 bp paired-end chemistry on an Illumina HiSeq 2500 platform (Illumina) at GATC Biotech AG, Germany.

Cells of *S. lugdunensis* APC 3758 were grown to mid-log phase in Tryptic Soy broth (TSB) and centrifuged at 2,400 *g* for 20 min. A 600 mg pellet of cells was then snap frozen by placing the centrifuge tube into ethanol which had been previously cooled for 24 h to -80°C . Chromosomal DNA was isolated by commercial sequence provider GATC Biotech, Ltd (Kostanz, Germany). Single-molecule real-time (SMRT) sequencing was performed on Pacific Biosciences RS II sequencing platform (executed by GATC Biotech, Ltd.).

The rapid sequencing kit (SQK-RAD004, Oxford Nanopore Technologies) was also used to prepare the *P. protegens* APC 3760 DNA library according to the manufacturer's instructions. *P. protegens* APC 3760 DNA was sequenced on a MinION device using R9.4 flow cell. The run duration was 24 h. Raw data was processed and basecalled using ONT Albacore Sequencing Pipeline Software (version 2.3.3).

Genome Assembly and Annotation

Following sequencing, Illumina adaptors were removed from fastq reads using CutAdapt (version 1.9.1; Martin, 2011). Paired-end adaptor-free reads were trimmed using Trimmomatic (version 0.32; Bolger et al., 2014) to a Phred score of 30 across a 4 bp sliding window. Surviving reads less than 70 bp were discarded. The final quality of reads was assessed using FastQC (version 0.11.5)². Finally, both paired and unpaired Illumina reads were assembled using SPAdes (version 3.10.0; Nurk et al., 2017). Assembly of complete *S. lugdunensis* APC 3758 genome from raw Pacific Biosciences SMRT reads was done using Flye (version 2.4.1). Hybrid draft assembly of *P. protegens* APC 3760 genome from trimmed Illumina HiSeq and raw ONT MinION reads was performed using SPAdes in 'careful' mode. Annotation of the genomes was provided by the SEED viewer and the RAST annotation server (Overbeek et al., 2014).

Bacteriocin *in silico* Identification

The bacteriocin mining tool BAGEL3 (van Heel et al., 2013) was used to identify putative bacteriocin operons in combination with antiSMASH5 (Blin et al., 2019) which detects secondary metabolites. The genome visualization tool CLC Sequence viewer 8.0 (CLC Bio, Qiagen, Aarhus, Denmark) was subsequently used for manual analysis of the bacterial genomes. To determine the degree of novelty in the bacteriocins identified by BAGEL3 and antiSMASH5, BLASTP (Altschul et al., 1990) searches were performed for each putative bacteriocin peptide against

¹<http://www.ncbi.nlm.nih.gov/BLAST/>

²<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>

TABLE 1 | Growth conditions for the indicator strains used in this study.

Growth conditions				
Species	Strain	Temperature (°C)	Atmosphere	Growth media
<i>Listeria monocytogenes</i>	L028	37	Aerobic	BHI, TSB, MH
	ATCC 33007			
	EDG-e			
<i>Bacillus cereus</i>	DPC 6087	37	Aerobic	BHI, TSB, MH
<i>B. subtilis</i>	NCTC 10073	37	Aerobic	BHI, TSB, MH
<i>Lactococcus lactis</i> subsp. <i>cremoris</i>	HP	30	Aerobic	GM17
<i>E. faecium</i>	DPC 3675	37	Aerobic	BHI, TSB, MH
<i>E. faecalis</i>	ATCC 29200	37	Aerobic	BHI, TSB, MH
	DPC 5152			
	DSM 2570			
	VRE V583			
<i>S. aureus</i>	APC 3759	37	Aerobic	BHI, TSB, MH
	DPC 5243			
	Newman			
	DPC 7673			
	RF122			
<i>M. luteus</i>	DSM 1790	37	Anaerobic	BHI, TSB, MH
<i>P. aeruginosa</i>	PA01	30	Aerobic	BHI, TSB, MH
MRSA	BSAC ST528	37	Aerobic	BHI, TSB, MH
	BSAC ST530			
<i>Escherichia coli</i>	MG 1655	37	Aerobic	LB
	0157			
<i>St. agalactiae</i>	ATCC 13813	37	Aerobic	TSB, MH
<i>St. uberis</i>	DPC 5344	37	Aerobic	TSB, MH
<i>C. kroppenstedtii</i>	APC 3845	37	Anaerobic	TSB, MH
<i>C. tuberculostearicum</i>	APC 3844	37	Anaerobic	TSB, MH
<i>Cutibacterium avidum</i>	APC 3846	37	Aerobic	TSB, MH
<i>St. salivarius</i>	APC 3843	37	Anaerobic	TSB, MH
<i>St. pyogenes</i>	DPC 6992	37	Anaerobic	TSB, MH
<i>Lactobacillus delbrueckii</i> subsp. <i>bulgaricus</i>	LMG 6901	37	Anaerobic	MRS

ATCC, American Type Culture Collection; APC, APC Microbiome Ireland Culture Collection; DPC, Teagasc Culture Collection; LMG, Laboratorium voor Microbiologie, Universiteit Gent, Belgium; NCTC, National Collection of Type Cultures, Public Health England; BSAC, British Society for Antimicrobial Chemotherapy; DSM, Leibniz Institute DSMZ – German Collection of Microorganisms and Cells Cultures.

those identified in the BAGEL and antiSMASH screen. The levels of identity described in this study are derived from MUSCLE. Structural peptides were aligned using the Multiple Sequence Alignment (MSA) tool MUSCLE (Edgar, 2004) and then visualized using Jalview (Waterhouse et al., 2009). Novelty was defined when there was a difference of two or more amino acids between the predicted bacteriocin and the one which was previously discovered.

RESULTS

Isolation of Potential Antimicrobial-Producing Human Milk Isolates

Thirty-seven lactating mothers were recruited who agreed to donate milk samples. Approximately 5,100 colonies isolated from these samples were screened against three indicator

organisms; *S. aureus* APC 3759, *Micrococcus luteus* DSM 1790 and *Pseudomonas aeruginosa* PA01. *S. aureus* APC 3759 was chosen as an indicator microorganism as it is not a bacteriocin producer and is just a representative strain. *P. aeruginosa* PA01 is a Gram-negative bacterial indicator whereas *M. luteus* DSM 1790 was selected based on its use to screen for antimicrobial activity (Janek et al., 2016; Wayah and Philip, 2018). No strain displayed inhibitory activity against *P. aeruginosa* PA01, but 174 potential antimicrobial-producing isolates were active against at least one of the other two indicators. Isolates with antimicrobial activity were identified in 25 out of 37 milk (67.6%) samples (data not shown).

One of the essential features of bacteriocin-producing bacteria is the requirement for immunity genes, which protect producers from the antimicrobial action of the bacteriocin they produce. Consequently, strains showing the same immunity pattern are likely to have the ability to produce the same bacteriocin(s). Based on the cross-immunity assay from 174 potential antimicrobial-producing isolates, 80 distinct

profiles were observed by eliminating strains that displayed cross-immunity and consequently suspected to produce the same or a very similar bacteriocin (**Supplementary Table S1**).

16S rRNA amplicon sequencing of the 80 antimicrobial-producing isolates revealed one Gram-negative bacterium namely *Pseudomonas protegens*, 47 *S. epidermidis* isolates, one *S. hominis*, one *S. lugdunensis*, 18 *S. aureus* isolates, one *Enterococcus faecalis*, and 11 *E. faecium* isolates. Subsequently, the genomes of the 80 identified isolates were sequenced to enable genome-mining to identify the antimicrobial encoding genes and their potential novelty.

Spectrum of Inhibition

We selected 29 of the 80 strains that exhibited the strongest inhibitory activity against the indicator organisms *S. aureus* APC 3759 and *M. luteus* DSM 1790 (data not shown) for examination of their inhibition spectra. **Table 2** shows the inhibition spectra of a panel of 29 antimicrobial producers against 29 indicators including known human mastitis pathogens such as *S. aureus* (Delgado et al., 2011), Methicillin Resistant *S. aureus* (MRSA) (Holmes and Zadoks, 2011), *Corynebacterium kroppenstedtii* (Wong et al., 2017) and *C. tuberculostearicum* (Paviour et al., 2002). The detected zones of inhibition could be attributed to any of the antimicrobial(s) produced by each of the tested strains. The antimicrobial produced by *E. faecalis* APC 3825 demonstrated the broadest spectrum of activity, inhibiting 19 of the indicator strains including vancomycin resistant *E. faecalis* V583, *S. aureus* APC 3759, *S. aureus* Newman, *S. aureus* DPC 5243, *St. pyogenes* DPC 6992, *C. tuberculostearicum* APC 3844 and the bovine mastitis pathogens *St. agalactiae* ATCC 13813 and *St. uberis* DPC 5344. *S. epidermidis* APC 3806, *S. epidermidis* APC 3804, and *S. epidermidis* APC 3782 inhibited 16, 15, and 14 of the indicators, respectively. All three of these *S. epidermidis* strains were isolated from the same donor (**Table 3**) yet their inhibition profile differed. *S. aureus* APC 3813 and *S. epidermidis* APC 3810 exhibited the narrowest inhibition spectra – inhibiting only three of the tested indicators. *S. lugdunensis* APC 3758 and *P. protegens* APC 3760 displayed inhibitory activity against the tested *S. aureus* strains, including the two MRSA strains, namely ST528 and ST530. Twenty-three of 29 strains inhibited the growth of *S. aureus* strains tested with only two impeding the specific MRSA strains tested. Representative zones of inhibition from a selection of the 29 potential bacteriocin producers are presented in **Figure 1**. None of the 29 potential bacteriocin producers inhibited *Corynebacterium kroppenstedtii* APC 3845, *Bacillus cereus* DPC 6087, *B. subtilis* NCTC 10073, *E. coli* MG1655 or *E. coli* O157.

Bacteriocin Identification

Bacteriocins are a divergent group of antimicrobials which utilize different systems for modification, transport, and immunity (Kotelnikova and Gelfand, 2002). We implemented an *in silico* approach to determine the diversity of the bacteriocins encoded by the 80 isolates which had a distinct immunity profile. The bacteriocin classification scheme suggested by Cotter et al. (2005, 2013) was used to distinguish between the different bacteriocin classes for Gram-positive bacteria with class I

including lantibiotics and class II including the non-lantibiotics. This screen led to 49 isolates that contained 73 potential bacteriocin gene clusters (PBGs) based on the predictions from BAGEL3 and antiSMASH5 (**Table 3** and **Figure 2**).

Additionally, BAGEL3 identified homologs of delta-lysins in 33 of the tested isolates and antiSMASH5 found genes associated with the production of terpenes, siderophores, polyketides (PKS), and Non-Ribosomal Peptide Synthetases (NRPSs) among a plethora of secondary metabolites (**Table 3**). Four potential bacteriocin gene clusters were excluded due to the absence of a detectable structural gene (*S. lugdunensis* APC 3758) or essential biosynthetic-associated genes (*P. protegens* APC 3760). Of the 69 bacteriocin gene clusters identified, one was identical to the previously characterized cytolysin from *E. faecalis* (Coburn and Gilmore, 2003), one to Enterocin 1071 (Balla et al., 2000) and three to the mature peptide of Enterocin P (Cintas et al., 1997) although in some cases the leader was atypical. The remaining 64 clusters represented potentially novel bacteriocin candidates belonging to class I ($n = 11$) and class II ($n = 53$) families. From the 64 potentially novel bacteriocin gene clusters (PBGs) identified, 16 potentially novel bacteriocin prepeptides were potentially produced by a single strain while the rest were identified in more than one isolate. A flow chart of the procedures followed is presented in **Figure 2**.

Similar to Egan et al. (2018), the homology of the predicted bacteriocin gene clusters to existing genes and their genetic arrangement were examined. Below we grouped PBGs by bacteriocin class.

Class I Bacteriocins

Class I bacteriocins are comprised of ribosomally produced, post-translationally modified bacteriocins (RIPPs). While initially lantibiotics were the sole occupant of class I bacteriocins, nowadays it includes more than 18 subclasses (Arnison et al., 2013).

Lantibiotics

The new lantibiotics predicted in this study (**Figure 3**) were grouped according to their amino acid similarity in order to facilitate comparison with previously characterized bacteriocins. Three lantibiotic gene clusters were detected in four genomes, including one classified as class IA and the remaining two as class IB (**Figure 3**). *S. epidermidis* APC 3775 and APC 3810 both potentially produce a class IA bacteriocin with a prepeptide displaying 81.8% similarity to epilancin 15X (Uniprot accession number: I6YXA9; Ekkelenkamp et al., 2005) and 24% to epidermin (P08136; Bierbaum et al., 1996) and contained the conserved domain PF08130 that corresponds to class IA lantibiotics.

In both of the strains encoding a class IA lantibiotic the bacteriocin modification, secretion, and immunity genes located within cluster type one (**Figure 3A**) exhibited strong similarities (>65%) to the bacteriocin-related genes of epilancin 15X (Elx, Velásquez et al., 2011). The cluster contained three putative immunity proteins, two modification enzymes (70.4% similarity with ElxC and 70.7% with ElxB), a protease (69.2% similarity with

TABLE 2 | Spectrum of inhibition of potential bacteriocin-producing human milk isolates against indicator strains by spot bioassays.

Isolates ↓/Indi cator →	<i>L.</i> <i>mono</i> <i>cyto</i> <i>genes</i> L028	<i>L.</i> <i>mono</i> <i>cyto</i> <i>genes</i> ATCC 33007	<i>L.</i> <i>mono</i> <i>cyto</i> <i>genes</i> EDGe	<i>L.</i> <i>lactis</i> HP	<i>M. lut</i> <i>eus</i> DSM 1790	<i>E. fae</i> <i>cium</i> DPC 3675	<i>E.</i> <i>faec</i> <i>alis</i> ATCC 29200	<i>E.</i> <i>faec</i> <i>alis</i> DPC 5152	<i>E.</i> <i>faec</i> <i>alis</i> DSM 2570	<i>E.</i> <i>faec</i> <i>alis</i> VRE V583	<i>S.</i> <i>aur</i> <i>eus</i> APC 3759	<i>S. aur</i> <i>eus</i> DPC 5243	<i>S. aur</i> <i>eus</i> New man	<i>S. aur</i> <i>eus</i> MRSA ST528	<i>S. aur</i> <i>eus</i> MRSA ST530	<i>S. aur</i> <i>eus</i> DPC 7673	<i>S. aur</i> <i>eus</i> RF122	<i>St.</i> <i>agala</i> <i>ctiae</i> ATCC 13813	<i>St.</i> <i>ube</i> <i>ris</i> ATCC 5344	<i>C.</i> <i>tuber</i> <i>culos</i> <i>tear</i> APC 3844	<i>C. avi</i> <i>dum</i> APC 3846	<i>St.</i> <i>saliv</i> <i>arius</i> APC 3843	<i>St.</i> <i>pyo</i> <i>genes</i> DPC 6992	<i>L. bulg</i> <i>aricus</i> LMG 6901	
<i>E. faecalis</i> APC 3825	1.5± 0.3			11.5± 0.6	9.9± 0.2	10.6± 0.3	11.7± 0.5	2.5± 0.7	1.4± 0.4	7.6± 0.9	9.9± 0.2	5.3± 0.5	9.9± 0.2					7.4± 0.2	12.7± 0.4	1.4± 0.4	5.3± 0.5	7.6± 0.9	7.9± 0.3		
<i>E. faecium</i> APC 3835	1.7± 0.2	5.1± 0.6	6.5± 0.6	4.9± 0.4			2.3± 0.3						2.1± 0.1					4.1± 0.4							
APC 3832	1.0± 0.2	4.7± 0.3	7.0± 0.5	5.3± 0.2		2.2± 0.3							2.5± 0.3												
APC 3836	1.5± 0.2	5.3± 0.5	7.0± 0.6	5.4± 0.2		2.1± 0.3	2.8± 0.2						2.7± 0.4						2.0± 0.6						
APC 3826	1.3± 0.2	5.8± 0.5	9.4± 0.5	5.2± 0.2		2.4± 0.2	2.0± 0.2						2.8± 0.6						2.0± 0.6						
APC 3830	1.0± 0.2	4.9± 0.5	7.2± 0.7	1.5± 0.4			2.8± 0.2						3.1± 0.2												
APC 3837	1.2± 0.2	5.0± 0.4	6.7± 0.4	6.3± 0.5									3.4± 0.1						1.9± 0.6						
APC 3831	1.1± 0.1	5.1± 0.4	6.2± 0.4	5.2± 0.6									4.5± 0.2						1.8± 0.6						
APC 3833		4.6± 0.4	6.5± 0.5	4.4± 0.3				4.4± 0.3					5.1± 0.3						4.2± 0.3						
APC 3829	2.2± 0.2		6.0± 0.4		4.2± 0.3								5.3± 0.2												
<i>S. epider</i> <i>midis</i> APC 3793					7.8± 0.3	9.7± 0.6	5.2± 0.2	6.0± 0.3		6.4± 0.4									5.8± 0.4						
APC 3803		3.0± 0.8		8.8± 0.5	4.0± 0.3	6.2± 0.3	4.1± 0.3	5.7± 0.4		5.3± 0.4									6.2± 0.4	5.9± 0.3					
APC 3801				13.6± 0.1	8.7± 0.4	8.7± 0.3	5.6± 0.4			6.4± 0.2		9.0± 0.5							6.4± 0.4	6.1± 0.3					
APC 3782	7.8± 0.5		6.0± 0.2		11.7± 0.5	12.6± 0.5	7.5± 0.3	12.0± 0.5		9.1± 0.4	4.5± 0.4					5.0± 0.3			12.0± 0.6	8.6± 0.4		7.4± 0.1	6.1± 0.8	7.4± 0.4	
APC 3804	5.0± 0.2		6.0± 0.2	17.3± 0.2	11.5± 0.4	5.8± 0.8	12.0± 0.4	11.9± 0.6		9.7± 0.5	6.0± 0.4					5.0± 0.4			11.0± 0.6	9.7± 0.3		9.0± 0.4	9.9± 0.5	6.6± 0.3	

(Continued)

TABLE 2 | Continued

Isolates ↓/Indicator →	<i>L. mono cyto genes</i> L028	<i>L. mono cyto genes</i> ATCC 33007	<i>L. mono cyto genes</i> EDGe	<i>L. lactis</i> HP	<i>M. luteus</i> DSM 1790	<i>E. faecium</i> DPC 3675	<i>E. faecalis</i> ATCC 29200	<i>E. faecalis</i> DPC 5152	<i>E. faecalis</i> DSM 2570	<i>E. faecalis</i> V583	<i>S. aureus</i> APC 3759	<i>S. aureus</i> DPC 5243	<i>S. aureus</i> New man	<i>S. aureus</i> MRSA ST528	<i>S. aureus</i> MRSA ST530	<i>S. aureus</i> DPC 7673	<i>S. aureus</i> RF122	<i>St. agalactiae</i> ATCC 13813	<i>St. uberis</i> ATCC 5344	<i>C. tuberculosis</i> tear APC 3844	<i>C. aviary</i> APC 3846	<i>St. salivarius</i> APC 3843	<i>St. pyogenes</i> DPC 6992	<i>L. bulgaricus</i> LMG 6901	
APC 3806	7.4± 0.2	1.5± 0.5		16.5± 0.7	10.3± 0.4	11.7± 0.3	8.6± 0.3	12.8± 0.2		9.2± 0.4	6.0± 0.2	9.1± 0.7					5.0± 0.2	10.9± 0.4	11.3± 0.4		10.3± 0.1	6.5± 0.8	5.9± 0.3		
APC 3810				5.6± 0.4								4.1± 0.2													7.9± 0.5
APC 3775				15.5± 0.2	7.0± 0.3	9.2± 0.3	5.5± 0.2	6.2± 0.2	7.7± 0.9	6.8± 0.4								5.8± 0.4	5.4± 0.3	11.1± 0.4		9.9± 0.4	6.1± 0.3		
<i>S. aureus</i>																									
APC 3774	3.6± 0.3			17.4± 0.3	14.3± 0.4	14.1± 0.5	6.5± 0.3	6.6± 0.2	8.9± 0.9	7.3± 0.4		10.3± 0.4						8.5± 0.3	6.3± 0.2	12.2± 0.5					
APC 3787	6.0± 0.3				7.9± 0.5	8.9± 0.4	6.7± 0.4	5.2± 0.3		6.0± 0.1								6.3± 0.3	6.3± 0.2						
APC 3887				20.0± 0.2	8.1± 0.3	7.6± 0.6	5.0± 0.3					11.5± 0.3													7.0± 0.3
APC 3809				9.7± 0.6	5.3± 0.6							8.7± 0.2						3.8± 0.3							7.4± 0.4
APC 3823				15.1± 0.2	9.1± 0.4							10.7± 0.2						2.7± 0.3							9.5± 0.3
APC 3813				9.6± 0.6	5.8± 0.3													5.2± 0.3							
APC 3822				3.9± 0.4	4.6± 0.5							5.3± 0.2						4.7± 0.5							
APC 3812				4.3± 0.4	4.8± 0.4													5.2± 0.4							3.1± 0.6
<i>S. hominis</i>						13.1± 0.5	7.8± 0.1			3.8± 0.6	4.7± 0.2														
APC 3824																									
<i>S. lugdunensis</i>											3.0± 0.2	3.0± 0.1	3.0± 0.2	3.1± 0.2	3.0± 0.2		2.9± 0.2							2.1± 0.2	
APC 3758																									
<i>P. protegens</i>											4.5± 0.3	4.0± 0.2	4.1± 0.3	3.5± 0.2	3.4± 0.4	2.9± 0.2	3.0± 0.2								
APC 3760																									

The numbers indicate the size of the inhibition zone with standard deviation. The zone size was measured as follows: diameter of zone – diameter of spot in millimeters. The experiment was performed in three independent replicates. None of the 29 potential bacteriocin producers inhibited *C. kroppenstedtii* APC 3845, *B. cereus* DPC 6087, *B. subtilis* NCTC 10073, *E. coli* MG1655 or *E. coli* O157.

TABLE 3 | Antimicrobial prediction by BAGEL3 and antiSMASH5 for the 80 bacterial isolates with distinct cross-immunity profile.

Donors	Strains	Bacteriocin		Delta-lysin	Siderophore	NRPS	CDPS	Phosphonate	Others
		BAGEL3	antiSmash5	BAGEL3	antiSmash5	antiSmash5	antiSmash5	antiSMASH5	antiSMASH5
H1	<i>S. aureus</i> APC 3809	Class IId	–	2	Aureusimine	–	–	Terpene	–
	<i>S. epidermidis</i> APC 3785	Sactibiotic	–	–	Staphyloferrin	1	–	–	–
	<i>S. epidermidis</i> APC 3771; APC 3761; APC 3762; APC 3763; APC 3764; APC 3766; APC 3769; APC 3770	–	–	1	Staphyloferrin	1	–	–	–
	<i>S. epidermidis</i> APC 3768; APC 3771; APC 3773	–	–	–	Staphyloferrin	1	–	–	–
	H2	<i>S. aureus</i> APC 3774	Class IId	–	–	2	Aureusimine	–	–
<i>S. epidermidis</i> APC 3810	Class IA; Class IId	–	1	Staphyloferrin	1	–	–	–	
<i>E. faecalis</i> APC 3825	Class IB; Class IIb	–	–	–	–	–	–	–	
<i>S. epidermidis</i> APC 3775	Class IA; Class IId; Sactibiotic	Class IA; Class IId	–	–	Staphyloferrin	1	–	–	–
H3	<i>E. faecium</i> APC 3827	Class IIa; Class IIc	–	–	–	–	–	–	–
	<i>S. epidermidis</i> APC 3776; APC 3777	–	–	1	Staphyloferrin	1	–	–	–
H4	<i>S. epidermidis</i> APC 3778	–	Class IIc	–	Staphyloferrin	1	–	–	–
	<i>S. epidermidis</i> APC 3779	–	Class IIb	–	Staphyloferrin	1	–	–	–
H5	<i>E. faecium</i> APC 3828; APC 3880	Class IIa; Class IIc	–	–	–	–	–	–	–
	<i>S. epidermidis</i> APC 3780	–	–	1	Staphyloferrin	1	–	–	–
	<i>S. aureus</i> APC 3821; APC 3881	–	–	–	2	Aureusimine	–	–	Terpene
	<i>S. aureus</i> APC 3829	Class IIc	–	–	2	Aureusimine	–	–	Terpene
	<i>S. epidermidis</i> APC 3882	Sactibiotic	–	1	Staphyloferrin	1	–	–	–
H6	<i>S. aureus</i> APC 3822	Class IIc	–	–	2	Aureusimine	–	–	Terpene
	<i>S. epidermidis</i> APC 3787; APC 3788; APC 3789; APC 3790; APC 3791	–	–	–	Staphyloferrin	1	–	–	–
H7	<i>S. epidermidis</i> APC 3792; APC 3793	–	–	1	Staphyloferrin	1	–	–	–
	<i>S. hominis</i> APC 3824	Class IB	–	–	1	–	–	1	–
	<i>S. epidermidis</i> APC 3794	Sactibiotic	–	1	Staphyloferrin	1	–	–	–
H8	<i>S. epidermidis</i> APC 3781; APC 3795; APC 3798	–	–	1	Staphyloferrin	1	–	–	–
	<i>S. epidermidis</i> APC 3796; APC 3797; APC 3883	Sactibiotic	–	1	Staphyloferrin	1	–	–	–

(Continued)

TABLE 3 | Continued

Donors	Strains	Bacteriocin		Delta-lysin	Siderophore	NRPS	CDPS	Phosphonate	Others
		BAGEL3	antiSmash5	BAGEL3	antiSmash5	antiSmash5	antiSmash5	antiSMASH5	antiSMASH5
H9	<i>S. epidermidis</i> APC 3799; APC 3800; APC 3803	–		1	Staphyloferrin	1	–	–	–
	<i>S. epidermidis</i> APC 3801; APC 3802	–	Class IIb	–	Staphyloferrin	1	–	–	–
H10	<i>S. epidermidis</i> APC 3804; APC 3805; APC 3806	Class IIc; Class IIc		1	Staphyloferrin	1	1	–	–
	<i>S. epidermidis</i> APC 3782	Sactibiotic; Class IIc; Class IIc	Class IIc; Class IIc	1	Staphyloferrin	1	1	–	–
H11	<i>S. epidermidis</i> APC 3783; APC 3784	–		–	Staphyloferrin	1	–	–	–
	<i>S. aureus</i> APC 3814	Class IIc		–	2	Aureusimine	–	–	Terpene
H12	<i>S. epidermidis</i> APC 3807	–		1	Staphyloferrin	1	1	–	–
H13	<i>S. epidermidis</i> 3808	Sactibiotic	–	1	Staphyloferrin	–	–	–	–
H14	<i>P. protegens</i> APC 3760	Putidacin L1-like	2	–	–	6	1	–	Type III PKS; Type I PKS; betalactone; pyrrolnitrin; homoserine lactone cluster; arylpolyene
H15	<i>S. lugdunensis</i> APC 3758	TOMM		–	1	3	1	–	Terpene
H16	<i>S. aureus</i> APC 3812; APC 3816; APC 3823;	Class IIc		–	2	Aureusimine	–	–	Terpene
H17	<i>S. aureus</i> APC 3813	Class IIc	–	–	2	Aureusimine	–	–	Terpene
H18	<i>S. aureus</i> APC 3818; APC 3884	Class IIc	–	–	2	Aureusimine	–	–	Terpene
H19	<i>S. aureus</i> APC 3885	–		–	2	Aureusimine	–	–	Terpene
	<i>S. aureus</i> APC 3886; APC 3887	Class IIc	–	–	2	Aureusimine	–	–	Terpene
H20	<i>S. aureus</i> APC 3819	Class IIc	–	–	2	Aureusimine	–	–	Terpene
	<i>E. faecium</i> APC 3830; APC 3831; APC 3832; APC 3833; APC 3835; APC 3837	Class IIa; Class IIc		–	–	–	–	–	–
H21	<i>S. aureus</i> APC 3820	Class IIc; Class IIc	–	1	2	Aureusimine	–	–	Terpene
H22	<i>S. aureus</i> APC 3815	Class IIc	–	1	2	Aureusimine	–	–	Terpene
H23	<i>E. faecium</i> APC 3826	Class IIa; Class IIc		–	–	–	–	–	–
H24	<i>E. faecium</i> APC 3836	Class IIa; Class IIc		–	–	–	–	–	–
H25	<i>E. faecium</i> APC 3827	Class IIa; Class IIc		–	–	–	–	–	–

The isolates are grouped per donor from whom the bacteria were isolated.




FIGURE 1 | Representative zones of inhibition from a selection of the 29 antimicrobial producers that demonstrated the strongest inhibition against *S. aureus* APC 3759 and *M. luteus* DSM 1790 against a selection of the 29 indicator strains.




FIGURE 2 | Flow chart of bacteriocin screening performed for this study. PBGC stands for Potential Bacteriocin Gene Cluster.



ElxP), an ABC transporter (80.8% similarity with ElxT) and a third modification enzyme (78.6% similarity with ElxT).

Cytolysin (Uniprot accession number: Q52052 and GenBank accession number: P08136), a two-component class IB lantibiotic, was identified in *E. faecalis* APC 3825 (IB cluster type 1; **Figure 3B**). An additional class IB bacteriocin gene cluster, was found in *S. hominis* APC 3824, encoding a complete class IB lantibiotic (IB, cluster type 2). In *S. hominis* APC 3824, peptide α displayed 28.8% amino acid similarity with haloduracin α while peptide β displayed 33.3% amino acid similarity to haloduracin β (**Figure 3B**). The operon of APC 3824 contained several lantibiotic-related genes including two LanM enzymes (conserved domain PF0145), a putative peptidase (conserved domain

PF00082) and two ABC transporters containing ATP-binding subunits (conserved domain PF00005). The operon also contained a two-component regulatory system comprised of a putative histidine kinase (conserved domain PF00512) and a putative transcriptional response regulator (conserved domains PF00072 and PF00486).

Sactibiotics

The sactibiotics are a subgroup of Class I bacteriocins that are characterized by intramolecular bridges between cysteine sulfur and α -carbon covalent bonds (Mathur et al., 2015). These modifications are performed by radical S-adenosylmethionine (SAM) proteins which catalyze the formation of these thioether bonds (Rea et al., 2010).



E. faecium APC 3826, 3827, 3828, 3832, 3836, and 3837 (IIa cluster type 1) belonged to the same bacteriocin gene cluster which contained two genes including a gene encoding a putative bacteriocin (conserved domain PF01721). The cluster also consisted of a gene encoding an immunity protein (Uniprot accession number O30435; 98.9% identity to EntP immunity protein). *E. faecium* APC 3830 was the sole isolate encoding a class IIa cluster type 2 (Figure 5B) that comprised two genes encoding bacteriocin-related proteins namely, immunity proteins. One of them was located downstream of the prepeptide (98.9% similarity to EntP immunity protein) while the second one (100% identity to EntP immunity protein) was located upstream of the structural gene (conserved domain PF01721). The bacteriocin gene cluster of *E. faecium* APC 3831 (IIa cluster type 3; Figure 5B) consisted of two bacteriocin-related genes.

Class IIa cluster type 3 comprised of an immunity protein (98.9% identity to immunity protein of EntP) located downstream of the structural gene (Figure 5B). *E. faecium* APC 3833, APC 3835, and APC 3880 encode the same gene cluster (IIa cluster type 4; Figure 5B) which is comparable to cluster type I apart from the absence of the gene encoding an ABC transporter.

Class IIb bacteriocins

Class IIb is comprised of two-peptide bacteriocins where the optimal antimicrobial activity requires the synergistic activity of both peptides (Nissen-Meyer et al., 2010). Two class IIb bacteriocin clusters were identified by BAGEL3 and antiSMASH5 (Figures 6A,B). BAGEL3 identified a bacteriocin gene cluster in *E. faecalis* APC 3825 where the prepeptide is 100% identical to Enterocin 1071 (Uniprot accession numbers: Q9L9U6 for

Enterocin 1071A and Q9L9U5 for Enterocin 1071B; Balla et al., 2000). A further class IIB operon was identified by antiSMASH5 in three *S. epidermidis* strains which were isolated from two milk samples (Table 3). The α prepeptide identified in *S. epidermidis* APC 3779, APC 3801, and APC 3802 was 36.4% similar to Lactococcin G α (Uniprot accession number C5IHS6; Moll et al., 1996; Figure 6A) while the β prepeptide displayed 24.0% identity with Lactococcin G β (Uniprot accession number C5IHS7; Figure 6A; Moll et al., 1996; Figure 6B).

The bacteriocin gene cluster identified in *E. faecalis* APC 3825 displayed similar genetic organization to Enterocin 1071 (Balla and Dicks, 2005) with the putative immunity gene being 39.8% similar to the immunity protein of Lactococcin G and located downstream of the structural α gene (conserved domains PF08129 and PF10439). The cluster also contained genes encoding an ABC transporter responsible for export and cleavage of the bacteriocin (conserved domains PF00005 and PF03412) and an accessory protein, both located upstream of the second structural gene (conserved domains PF08129 and PF10439; Figure 6C). A second bacteriocin gene cluster was identified in three *S. epidermidis* isolates, namely APC 3779, APC 3801, and APC 3802. The identified bacteriocin gene cluster contained simple genetic organization with the gene encoding an ABC transporter (conserved domains PF00005 and PF03412) being located upstream of the α structural gene (Figure 6C).

Class IIC bacteriocins

Class IIC bacteriocins are known as circular bacteriocins because of the covalent linkage of the N- to C- termini. Apart from being highly hydrophobic, known members of class IIC bacteriocins display little homology to each other (Martin-Visscher et al., 2011). These bacteriocins act by targeting the cytoplasmic membrane leading to pore formation and eventual cell death (Perez et al., 2018).

Five potential class IIC bacteriocins (NCBI conserved domain TIGR03651) were detected (Figure 7A). More specifically, one potential class IIC bacteriocin was found in three *S. epidermidis* strains (APC 3782, APC 3804, and APC 3805) which were isolated from the same milk sample (Table 3) and displayed only 30.8% similarity to the circular bacteriocin Enterocin NKR-5-3B (Himeno et al., 2015; Uniprot accession number A0A0P0YL94). Moreover, a second putative class IIC bacteriocin was found in *S. epidermidis* APC 3778 with the prepeptide being 26.2% similar to Enterocin NKR-5-3B (Figure 7A). A third class IIC bacteriocin was detected in ten *S. aureus* strains (APC 3813, APC 3814, APC 3815, APC 3818, APC 3819, APC 3820, APC 3822, APC 3884, APC 3886, APC 3887) isolated from eight milk samples (Table 3) and the detected prepeptide was 30.1% similar to Enterocin NKR-5-3B (Uniprot accession number A0A0P0YL94). Furthermore, a fourth class IIC prepeptide was detected in *S. aureus* APC 3829 which exhibited 24.2% similarity to Enterocin NKR-5-3B (Figure 7A). Finally, a fifth class IIC prepeptide was found in 11 *E. faecium* strains (APC 3826, APC 3827, APC 3828, APC 3830, APC 3831, APC 3832, APC 3833, APC 3835, APC 3836, APC 3837, and APC 3880) isolated from six milk samples (Table 3)

with the prepeptide sharing 95.4% similarity to Enterocin NKR-5-3B (Uniprot accession number A0A0P0YL94).

Five putative bacteriocin gene clusters for circular bacteriocins were identified (Figure 7B). Class IIC cluster type 1 is comprised of the three *S. epidermidis* strains (APC 3782, APC 3804, and APC 3805) and exhibits a simple genetic organization. The cluster was comprised of a gene encoding an ABC transporter containing an ATP-binding domain (conserved domain PF00005) located upstream of the putative bacteriocin (Figure 7B). *S. epidermidis* APC 3778 contained a bacteriocin gene cluster (Class IIC cluster type 2; Figure 7B) which consisted of a gene encoding an ABC transporter with a peptidase domain for cleaving the leader (conserved domains PF00005 and PF03412) located upstream of the putative bacteriocin. All ten *S. aureus* strains had the same organization in the bacteriocin gene cluster (IIC cluster type 3) which contained several bacteriocin-related genes including a transcriptional regulator and an ABC transporter containing an ATP-binding subunit. The bacteriocin gene cluster also consisted of genes encoding an ABC transporter composed of ATP-binding and permease subunits (conserved domain PF00005) located upstream of the putative structural gene (Figure 7B). *S. aureus* APC 3829 encoded a bacteriocin gene cluster (class IIC cluster type 4) which contained a transcriptional regulator and an ABC transporter (conserved domain PF00005) flanking the structural gene (Figure 7B). Within the 11 *E. faecium* strains, sharing identical structural genes, three subclasses were defined based on the organization of the gene clusters. All sub-clusters comprised of genes encoding an ABC transporter that contained ATP-binding and permease subunits (conserved domain PF00005). The sub-clusters were also composed of genes encoding a putative histidine kinase, a putative accessory protein regulator B gene and a response regulator transcription factor. The transcription factors are implicated in bacteriocin regulation, although it is not yet known to which of the two (class IIC or class IIA) bacteriocins they belong (class IIC cluster type 5a-5c; Figure 7B).

Class IID bacteriocins

Class IID bacteriocins are linear, single peptide bacteriocins that display no homology to class IIA bacteriocins (Cotter et al., 2013). One member of this class is Lactococcin 972, which is encoded as a 91-amino-acid prepeptide that includes a 25-amino-acid sec-dependent signal peptide and the final mature peptide (66 amino acids) (Martínez et al., 1999). Lactococcin 972 inhibits the growth of susceptible cells by interfering with septum formation (Martínez et al., 2000).

Two class IID prepeptides were identified in the study with the first being detected in six *S. epidermidis* strains identified from two human milk samples and displayed 21.1% similarity with Lactococcin 972 (Uniprot accession number: O86283; Figure 8A). The second was found in six *S. aureus* strains which were isolated from four human milk samples and was 36.3% similar to Lactococcin 972 (Uniprot accession number: O86283; Figure 8A).

Two bacteriocin class IID gene clusters were detected in this study with one being identical in all *S. epidermidis* (class IID cluster type 1) genomes while the other one was identical in all




FIGURE 6 | Multiple Sequence Alignments (MSA) of class IIb bacteriocin prepeptides and biosynthetic gene clusters. **(A)** MSA of the identified class IIb α prepeptides and known bacteriocins Enterocin 1071 (Uniprot accession number for α : Q9L9J6) and Lactococcin G (Uniprot accession number for α : C5IHS6). **(B)** MSA of the identified class IIb β prepeptides and known bacteriocins Enterocin 1071 (Uniprot accession number for β : Q9L9J5) and Lactococcin G (Uniprot accession number for β : C5IHS7). *Efaec* stands for *E. faecalis* and *Sep* corresponds to *S. epidermidis*. The same prepeptides were identified in *S. epidermidis* APC 3779, APC 3801, and APC 3802. **(C)** Biosynthetic gene clusters of identified class IIb bacteriocins.




FIGURE 7 | Multiple Sequence Alignments (MSA) of class IIc bacteriocin prepeptides and biosynthetic gene clusters. **(A)** MSA of the identified class IIc prepeptides and known bacteriocin EnterocinNKR-5-3B (Uniprot accession number A0A0P0YL94). *Sep* corresponds to *S. epidermidis*, *Sa* stands for *S. aureus* and *Ef* for *E. faecium*. The same prepeptide was identified in *S. epidermidis* APC 3782, APC 3804, and APC 3805. The same prepeptide was detected in *S. aureus* APC 3813, APC 3814, APC 3815, APC 3818, APC 3819, APC 3820, APC 3822, APC 3884, APC 3886, and APC 3887. Also, identical prepeptide was found in the genomes of *E. faecium* APC 3826, APC 3827, APC 3828, APC 3830, APC 3831, APC 3832, APC 3833, APC 3835, APC 3836, APC 3837, and APC 3880. **(B)** Biosynthetic gene clusters of identified class IIc bacteriocins. Class IIc-related proteins are surrounded by a dashed box while class IIa-related proteins are encompassed in a solid box.

S. aureus genomes (class IId cluster type 2; **Figure 8B**). Class IId cluster type 1 displayed a simple genetic organization with genes encoding an ABC transporter containing a permease and an ATP-binding subunit (conserved domain PF00005), being located downstream of the structural gene (**Figure 8B**). Class IId cluster type 2 on the other hand, exhibited a different genetic organization and contained several bacteriocin-related genes including a putative immunity gene upstream of the structural

gene and an ABC transporter containing a permease domain (conserved domain PF00005).

DISCUSSION

This study aimed to characterize bacteriocin producing strains isolated from healthy milk samples, combining both *in silico*




FIGURE 8 | Multiple Sequence Alignments (MSA) of class IId bacteriocin prepeptides and biosynthetic gene clusters. **(A)** MSA of the identified class IId prepeptides and known bacteriocin Lactococcin 972 (Uniprot accession number O86283). *Sep* corresponds to *S. epidermidis* and *Sa* stands for *S. aureus*. The same prepeptide was identified in *S. epidermidis* APC 3775, APC 3782, APC 3804, APC 3805, APC 3806, and APC 3810. The same prepeptides were detected in *S. aureus* APC 3774, APC 3809, APC 3812, APC 3813, APC 3816, APC 3820, and APC 3823. **(B)** Biosynthetic gene clusters of identified class IId bacteriocins.

and *in vitro* screening methods. This combinatorial approach enabled a more comprehensive estimation of bacteriocin production associated with human breast milk. Nevertheless, bacteriocin production can be a highly regulated process with strains requiring specific conditions and environments to induce production of these antimicrobials (Diep et al., 2000; Maldonado-Barragan et al., 2013). Therefore, the use of BAGEL3 and antiSMASH5 for bacteriocin screening facilitated the identification of bacteriocin operons in the 80 isolates with distinct immune profiles without the drawbacks and constraints of *in vitro* screening.

We screened strains isolated from the milk of 37 asymptomatic donors and found that 25 donors (67.6%) harbored strains with antimicrobial activity (Table 3) under the conditions tested. The isolated strains from the milk could have originated from the mother’s skin, the infant’s oral cavity, and/or the entero-mammary pathway (Angelopoulou et al., 2018), thus we cannot be certain about the source. During the initial screening, we observed activity against *S. aureus* APC 3759 and/or *M. luteus* DSM 1790. However, none of the strains exhibited activity against *P. aeruginosa* PA01 which is not unexpected, as bacteriocins produced by Gram-positive bacteria generally do not inhibit Gram-negative bacteria (Nikaido and Vaara, 1985; Nikaido, 2003). The majority of the bacterial species identified in this study encoding bacteriocin gene clusters are also known to encode virulence factors (Giormezis et al., 2015; Chessa et al., 2016; Madsen et al., 2017). Moreover, *S. aureus* and *S. epidermidis* are known as opportunistic pathogens in human mastitis (Angelopoulou et al., 2018). In addition, *Staphylococcus* and *Pseudomonas* belong to the healthy core milk microbiota (Boix-Amorós et al., 2016; Padilha et al., 2019). Among the isolated bacteria with high antimicrobial activity, it is notable the almost complete absence of members of the LAB group, with either high antimicrobial activity or encoding potential bacteriocins.

Cross-immunity screening resulted in the identification of 80 isolates with distinct profiles. Interestingly, strains *S. epidermidis* APC 3761, APC 3769, and APC 3772 came from the same donor (Table 3) yet they exhibited different cross-immunity profiles. However, these strains, also demonstrated immunity

to the bacteriocin(s) produced by others of the same species, suggesting that these three strains might be distinct. In contrast, *S. epidermidis* APC 3765 and *S. epidermidis* APC 3790 demonstrated identical cross-immunity profiles even though they originated from different donors. This may be explained by the fact that different people harbor bacteria that produce the same bacteriocin(s). A similar situation was observed for *E. faecium* APC 3828, APC 3833, APC 3834, *Lactobacillus gasseri* APC 3841 and *C. kroppenstedtii* APC 3845, which exhibited identical immunity profiles though they originated from different donors and were produced by different species. We observed the same phenomena with other strains (Supplementary Table S1).

The combined use of BAGEL3 and antiSMASH5 in conjunction with the applied criteria led to the identification of 64 novel bacteriocin gene clusters. Among them, 16 (25%) novel bacteriocins were found while the remaining 48 bacteriocin gene clusters were identified in more than one isolate. The identified peptides belonged to all bacteriocin classes and included two lantibiotics, four sactibiotics, three class IIa, one class IIb, four circular (class IIc) and two class IId bacteriocins. This confirms that human milk is a rich source of bacteriocin producing strains. The identified bacteriocins targeted major human and bovine mastitis pathogens such as *S. aureus*, *C. tuberculoostearicum* and *St. agalactiae* implying that breast milk microbiota could potentially play a beneficial role in the mammary health of lactating women by preventing breast infections and inflammation (Hunt et al., 2011). Some of the bacteriocin producing strains also potentially produce toxins. In contrast, bacteriocin producers have the potential to alter the intestinal ecology (Murphy et al., 2013), this may apply to the mammary gland of lactating women and could also influence the infant gastrointestinal tract (GIT) microbiota and the endogenous immune system, reinforcing the benefits of continued breastfeeding.

In the majority of the genomes ($n = 66$), antiSMASH5 identified secondary metabolites with potential antimicrobial activities, among others siderophores (Kohira et al., 2016), NRPSs including a lugdunin producer (a recently found thiazolidine-containing cyclic peptide antibiotic that prohibits colonization by *S. aureus*) (Zipperer et al., 2016), PKS (Zhang et al., 2014;

Li et al., 2018), terpenes (Gallucci et al., 2009; Zengin and Baysal, 2014), and pyrrolinitrin (el-Banna and Winkelmann, 1998). In 32 of the isolates, BAGEL3 also identified delta-lysins, which are members of the hemolytic polypeptide family toxins produced by staphylococci and known for their antimicrobial activity (Al-Mahrous et al., 2010). However, little is known about the regulation of the production of the aforementioned secondary metabolites in natural environments such as human milk.

Our study identified three lantibiotic gene clusters, one class IA and two class IB, from four isolates. Lantibiotics are small peptides that contain internal thioether bridges due to the interaction of dehydroalanine (Dha) or dehydrobutyrine (Dhb) with intrapeptide cysteines, resulting in the formation of (β -methyl)lanthionine residues (Lan/MeLan; McAuliffe et al., 2000). The formation of Lan/MeLan is catalyzed by LanB and LanC in class IA lantibiotics such as nisin with LanB catalyzing the dehydration of amino acids and LanC catalyzing thioether formation (Marsh et al., 2010). The biosynthesis of class IB lantibiotics is catalyzed by a single LanM enzyme with both dehydratase and cyclase activity. Class IA prepeptides have an FNLD conserved region at positions -15 and -20 and a proline at -2 from the cleavage site. These play an important role in peptide modifications (Lubelski et al., 2008). The LanA identified in *S. epidermidis* APC 3775 and APC 3810 possessed an FDLN motif with the proline at -2 similar to epilancin 15X (Ekkelenkamp et al., 2005).

Four sactibiotics were identified in our study with no similarities to previously characterized peptides. The *in silico* mining identified a histidine kinase and a response regulator, suggesting that the bacteriocins are subjected to a two-component regulatory system, previously reported in bovine non-*aureus* staphylococci (Carson et al., 2017).

Despite the fact that the majority of the identified bacteriocin gene clusters were class II, only ten prepeptides were unique. We identified three novel class IIa bacteriocins in 11 *E. faecium* isolates. The novel prepeptides contained a highly conserved consensus sequence in the N-terminus of YDNGI motif instead of the “pediocin box” YGNGV which is typical of the class (Drider et al., 2006). This is the first time that a different pediocin-box has been reported with the already known class IIa bacteriocins having a highly conserved pediocin box except where V can be occasionally replaced by L (Cui et al., 2012). *E. faecium* APC 3830, APC 3833, APC 3835, and APC 3880 have the potential to produce the same class IIa bacteriocin. The core peptide is 100% homologous to enterocin P though the signal peptide is somewhat different (two amino acid difference). The different leader could impact the optimal secretion of the bacteriocin and the maturation of the pre-bacteriocin by the ABC transporter as was demonstrated by Aucher et al. (2005). In that study, site-directed mutagenesis of the leader sequence of mesentericin Y105 revealed that the conserved hydrophobic amino acids and the C-terminal GG doublet of the leader are of critical importance for the secretion and maturation of the bacteriocin.

Four potential circular (class IIc) bacteriocins were identified with similarities to Enterocin NKR-5-3B, with the majority of the circular bacteriocins in staphylococci being detected in *S. aureus* according to the existing literature (Bastos

et al., 2009). Here, we identified putative novel circular bacteriocins from *S. epidermidis*, *S. aureus*, and *E. faecium* which displayed the highest similarity to Enterocin NKR-5-3B. All of the detected putative prepeptides contained the conserved domain linked with the circularin A/uberolysin family (TIGR03651). To date, there are only 14 circular bacteriocins that have been characterized (Perez et al., 2018) and much of the biosynthetic mechanisms including the circularization process as well as the regulatory mechanisms for production remain largely unknown. This study provides an additional four novel members (an increase of $\sim 25\%$) that may help to further elucidate the biosynthesis of this intriguing class of bacteriocins.

Two class IIc bacteriocins which are linear non-pediocin like bacteriocins were found in this study. The two class IIc clusters exhibited some degree of similarity with each other and at the same time both of them contained the lactococcin 972 conserved domain. Usually bacteriocins similar to lactococcin display a narrow spectrum activity against *Lactococcus* mainly because of the manner in which they bind to receptors (Kjos et al., 2009). However, this was not the case here as the detected strains exhibited wider inhibition spectra and displayed activity against a wide variety of the tested indicators. For example, *S. aureus* APC 3774 was active against *L. monocytogenes*, *E. faecalis*, *S. aureus*, and *M. luteus* among others which could potentially suggest the production of additional antimicrobials.

We identified 16 novel biosynthetic clusters belonging to all bacteriocin sub-classes across 25 human milk samples. The latter suggests not only a high degree of diversity of bacteriocins in human milk but also that it can be regarded as a promising source of novel metabolites including bacteriocins with potential implications in host defense and immune modulatory effects. Moreover, this study highlights the importance of a targeted approach to discover new effective antimicrobials that could potentially be applied to maintain good health in humans. It is anticipated that over the next few years, the number of sequenced genomes will drastically increase due to the widespread use of Next-Generation Sequencing (NGS) and the lower cost of Whole Genome Sequencing (WGS) which is empowered by third generation sequencing technologies, such as PacBio (Rhoads and Au, 2015) and Oxford Nanopore (Lu et al., 2016). With this expected proliferation in genome sequence data, there is equally a need for phenotypic trait surveying of strains such as described here to gain a more comprehensive understanding of bacteriocin-mediated interactions among coexisting species in natural communities such as human milk. The latter suggests that an increasing experimental effort to gain a more comprehensive understanding of bacteriocin mediated interactions among coexisting bacterial species in natural communities is warranted.

DATA AVAILABILITY STATEMENT

The datasets generated for this study were submitted to GenBank under BioProject number PRJNA521309.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Cork Clinical Research Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

AA performed the experiments and drafted the manuscript. AW advised on the screening and critically reviewed the manuscript. SS assembled the genomes and critically reviewed the manuscript. AS assembled the genomes of *P. protegens* APC 3760 and *S. lugdunensis* APC 3758, uploaded the genomes to NCBI, and critically reviewed the manuscript. PO'C, DF, LD, CS, and CH critically reviewed the manuscript. RR conceived the original idea and critically reviewed the manuscript.

FUNDING

This work was funded by APC Microbiome Ireland, a Centre for Science and Technology (CSET) funded by the Science Foundation Ireland (SFI), grant number SFI/12/RC/2273.

REFERENCES

- Abou-Dakn, M., Richardt, A., Schaefer-Graf, U., and Wöckel, A. (2010). Inflammatory breast diseases during lactation: milk stasis, puerperal mastitis, abscesses of the breast, and malignant tumors – current and evidence-based strategies for diagnosis and therapy. *Breast Care*. 5, 33–37. doi: 10.1159/000272223
- Algburi, A., Zehm, S., Netrobov, V., Bren, A. B., Chistyakov, V., and Chikindas, M. L. (2017). Subtilisin prevents biofilm formation by inhibiting bacterial quorum sensing. *Probiotics Antimicrob Proteins*. 9, 81–90. doi: 10.1007/s12602-016-9242-x
- Al-Mahrous, M., Sandiford, S. K., Tagg, J. R., and Upton, M. (2010). Purification and characterization of a novel delta-lysin variant that inhibits *Staphylococcus aureus* and has limited hemolytic activity. *Peptides*. 31, 1661–1668. doi: 10.1016/j.peptides.2010.06.006
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. *J. Mol. Biol.* 215, 403–410. doi: 10.1016/S0022-2836(05)80360-2
- Angelopoulou, A., Field, D., Ryan, C. A., Stanton, C., Hill, C., and Ross, R. P. (2018). The microbiology and treatment of human mastitis. *Med. Microbiol. Immunol.* 207, 83–94. doi: 10.1007/s00430-017-0532-z
- Angelopoulou, A., Harris, H. M. B., Warda, A. K., O'Shea, C.-A., Ryan, C. A., Stanton, C., et al. (2020). Subclinical mastitis, a frequent but misidentified disease in lactating women. *Pediatrics* (in press).
- Arnison, P. G., Bibb, M. J., Bierbaum, G., Bowers, A. A., Bugni, T. S., Bulaj, G., et al. (2013). Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. *Nat. Prod. Rep.* 30, 108–160. doi: 10.1039/c2np20085f
- Aucher, W., Lacombe, C., Hequet, A., Frere, J., and Berjeaud, J. M. (2005). Influence of amino acid substitutions in the leader peptide on maturation and secretion of mesentericin Y105 by *Leuconostoc mesenteroides*. *J. Bacteriol.* 187, 2218–2223. doi: 10.1128/JB.187.6.2218-2223.2005

ACKNOWLEDGMENTS

The authors would like to thank the mothers involved in this study for the kind donation of their milk. Also, the authors would like to extend their most grateful thanks to Professor C. Anthony Ryan for securing ethical approval and Ms. Carol-Anne O'Shea, Ms. Grainne Meehan, and Ms. Clare Boyle for assisting with sample collection.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2020.00788/full#supplementary-material>

TABLE S1 | Cross-immunity assays using overnight cultures from all the antimicrobial-producing strains tested against themselves and each other, with the list of antimicrobial-producing isolates down the left-hand side and the indicator strains across the top of the table. The dark green box represents inhibition of the indicator strain grown in TSB indicating that these strains might be different or sensitive to each other while light green box represents hazy zones. The yellow box represents inhibition of the indicator strain grown in MH indicating that these strains might be different or sensitive to each other while light yellow represents hazy zones. Dark blue box represents inhibition of the indicator strain grown in both conditions while light blue represents hazy zones. White boxes represent no inhibition, revealing target strains not being inhibited by the producing strain, indicating they are immune (related) to the bacteriocins produced by other producers.

- Balla, E., Dicks, L. M., Du Toit, M., Van Der Merwe, M. J., and Holzapfel, W. H. (2000). Characterization and cloning of the genes encoding enterocin 1071A and enterocin 1071B, two antimicrobial peptides produced by *Enterococcus faecalis* BFE 1071. *Appl. Environ. Microbiol.* 66, 1298–1304. doi: 10.1128/aem.66.4.1298-1304.2000
- Balla, E., and Dicks, L. M. T. (2005). Molecular analysis of the gene cluster involved in the production and secretion of enterocins 1071A and 1071B and of the genes responsible for the replication and transfer of plasmid pEF1071. *Int. J. Food Microbiol.* 99, 33–45. doi: 10.1016/j.ijfoodmicro.2004.08.008
- Bastos, M. C., Ceotto, H., Coelho, M. L., and Nascimento, J. S. (2009). Staphylococcal antimicrobial peptides: relevant properties and potential biotechnological applications. *Curr. Pharm. Biotechnol.* 10, 38–61. doi: 10.2174/138920109787048580
- Biagi, E., Quercia, S., Aceti, A., Beghetti, I., Rampelli, S., Turroni, S., et al. (2017). The bacterial ecosystem of mother's milk and infant's mouth and gut. *Front. Microbiol.* 8:1214. doi: 10.3389/fmicb.2017.01214
- Bierbaum, G., Götz, F., Peschel, A., Kupke, T., van de Kamp, M., and Sahl, H.-G. (1996). The biosynthesis of the lantibiotics epidermin, gallidermin, Pep5 and epilancin K7. *Antonie van Leeuwenhoek*. 69, 119–127. doi: 10.1007/BF00399417
- Blin, K., Shaw, S., Steinke, K., Villebro, R., Ziemert, N., Lee, S. Y., et al. (2019). antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. *Nucleic Acids Res.* 47, W81–W87. doi: 10.1093/nar/gkz310
- Boix-Amorós, A., Collado, M. C., and Mira, A. (2016). Relationship between milk microbiota, bacterial load, macronutrients, and human cells during lactation. *Front Microbiol.* 7:492. doi: 10.3389/fmicb.2016.00492
- Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30, 2114–2120. doi: 10.1093/bioinformatics/btu170
- Cabrera-Rubio, R., Mira, A., Isolauri, E., Laitinen, K., Salminen, S., and Collado, M. C. (2012). The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. *Am. J. Clin. Nutr.* 96, 544–551. doi: 10.1017/S2040174415001397

- Carson, D. A., Barkema, H. W., Naushad, S., and De Buck, J. (2017). Bacteriocins of non-*aureus* staphylococci isolated from bovine milk. *Appl. Environ. Microbiol.* 83, e1015–e1017. doi: 10.1128/AEM.01015-17
- Chessa, D., Ganau, G., Spiga, L., Bulla, A., Mazzarello, V., Campus, G. V., et al. (2016). *Staphylococcus aureus* and *Staphylococcus epidermidis* virulence strains as causative agents of persistent infections in breast implants. *Plos One* 11:e0146668. doi: 10.1371/journal.pone.0146668
- Chikindas, M. L., Weeks, R., Drider, D., Chistyakov, V. A., and Dicks, L. M. (2018). Functions and emerging applications of bacteriocins. *Curr. Opin. Biotechnol.* 49, 23–28. doi: 10.1016/j.copbio.2017.07.011
- Cintas, L. M., Casaus, P., Håvarstein, L. S., Hernández, P. E., and Nes, I. F. (1997). Biochemical and genetic characterization of enterocin P, a novel sec-dependent bacteriocin from *Enterococcus faecium* P13 with a broad antimicrobial spectrum. *Appl. Environ. Microbiol.* 63, 4321–4330. doi: 10.1128/aem.63.11.4321-4330.1997
- Civardi, E., Garofoli, F., Tzialla, C., Paolillo, P., Bollani, L., and Stronati, M. (2013). Microorganisms in human milk: lights and shadows. *J. Matern. Fetal. Neonatal Med.* 26, 30–34. doi: 10.3109/14767058.2013.829693
- Coburn, P. S., and Gilmore, M. S. (2003). The *Enterococcus faecalis* cytotoxin: a novel toxin active against eukaryotic and prokaryotic cells. *Cell Microbiol.* 5, 661–669. doi: 10.1046/j.1462-5822.2003.00310.x
- Collado, M. C., Delgado, S., Maldonado, A., and Rodríguez, J. M. (2009). Assessment of the bacterial diversity of breast milk of healthy women by quantitative real-time PCR. *Lett. Appl. Microbiol.* 48, 523–528. doi: 10.1111/j.1472-765X.2009.02567.x
- Collins, F. W. J., O'Connor, P. M., O'Sullivan, O., Gómez-Sala, B., Rea, M. C., Hill, C., et al. (2017). Bacteriocin gene-trait matching across the complete *Lactobacillus* pan-genome. *Sci. Rep.* 7:3481. doi: 10.1038/s41598-017-03339-y
- Cotter, P. D., Hill, C., and Ross, R. P. (2005). Bacteriocins: developing innate immunity for food. *Nat. Rev. Microbiol.* 3, 777–788. doi: 10.1038/nrmicro1273
- Cotter, P. D., Ross, R. P., and Hill, C. (2013). Bacteriocins — a viable alternative to antibiotics? *Nat. Rev. Microbiol.* 11, 95–105. doi: 10.1038/nrmicro2937
- Crispie, F., Twomey, D., Flynn, J., Hill, C., Ross, P., and Meaney, W. (2005). The lantibiotic lactacin 3147 produced in a milk-based medium improves the efficacy of a bismuth-based teat seal in cattle deliberately infected with *Staphylococcus aureus*. *J. Dairy Res.* 72, 159–167. doi: 10.1017/S0022029905000816
- Cui, Y., Zhang, C., Wang, Y., Shi, J., Zhang, L., Ding, Z., et al. (2012). Class IIA bacteriocins: diversity and new developments. *Int. J. Mol. Sci.* 13, 16668–16707. doi: 10.3390/ijms131216668
- Delgado, S., Garcia, P., Fernandez, L., Jimenez, E., Rodriguez-Banos, M., del Campo, R., et al. (2011). Characterization of *Staphylococcus aureus* strains involved in human and bovine mastitis. *FEMS Immunol. Med. Microbiol.* 62, 225–235. doi: 10.1111/j.1574-695X.2011.00806.x
- Diep, D. B., Axelsson, L., Grefslí, C., and Nes, I. F. (2000). The synthesis of the bacteriocin sakacin A is a temperature-sensitive process regulated by a pheromone peptide through a three-component regulatory system. *Microbiology* 146, 2155–2160. doi: 10.1099/00221287-146-9-2155
- Drider, D., Fimland, G., Héchar, Y., McMullen, L. M., and Prévost, H. (2006). The continuing story of class IIA bacteriocins. *Microbiol. Mol. Biol. Rev.* 70, 564–582. doi: 10.1128/MMBR.00016-05
- Edgar, R. C. (2004). MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* 32, 1792–1797. doi: 10.1093/nar/gkh340
- Egan, K., Field, D., Ross, R. P., Cotter, P. D., and Hill, C. (2018). In silico prediction and exploration of potential bacteriocin gene clusters within the bacterial genus *Geobacillus*. *Front. Microbiol.* 9:2116. doi: 10.3389/fmicb.2018.02116
- Eijsink, V. G., Axelsson, L., Diep, D. B., Havarstein, L. S., Holo, H., and Nes, I. F. (2002). Production of class II bacteriocins by lactic acid bacteria; an example of biological warfare and communication. *Antonie Van Leeuwenhoek* 81, 639–654. doi: 10.1023/A:1020582211262
- Ekkelenkamp, M. B., Hanssen, M., Danny Hsu, S. T., de Jong, A., Milatovic, D., and Verhoef, J. (2005). Isolation and structural characterization of epilancin 15X, a novel lantibiotic from a clinical strain of *Staphylococcus epidermidis*. *FEBS Lett.* 579, 1917–1922. doi: 10.1016/j.febslet.2005.01.083
- el-Banna, N., and Winkelmann, G. (1998). Pyrrolnitrin from *Burkholderia cepacia*: antibiotic activity against fungi and novel activities against streptomycetes. *J. Appl. Microbiol.* 85, 69–78. doi: 10.1046/j.1365-2672.1998.00473.x
- Fernández, L., Delgado, S., Herrero, H., Maldonado, A., and Rodríguez, J. M. (2008). The bacteriocin nisin, an effective agent for the treatment of staphylococcal mastitis during lactation. *J. Hum. Lact.* 24, 311–316. doi: 10.1177/0890334408317435
- Fernández, L., Langa, S., Martín, V., Maldonado, A., Jimenez, E., Martín, R., et al. (2013). The human milk microbiota: origin and potential roles in health and disease. *Pharmacol. Res.* 69, 1–10. doi: 10.1016/j.phrs.2012.09.001
- Gallucci, M. N., Oliva, M., Casero, C., Dambolena, J., Luna, A., Zygadlo, J., et al. (2009). Antimicrobial combined action of terpenes against the food-borne microorganisms *Escherichia coli*, *Staphylococcus aureus* and *Bacillus cereus*. *Flavour Fragr. J.* 24, 348–354. doi: 10.1002/ffj.1948
- Giormezis, N., Kolonitsiou, F., Makri, A., Vogiatzi, A., Christofidou, M., Anastassiou, E. D., et al. (2015). Virulence factors among *Staphylococcus lugdunensis* are associated with infection sites and clonal spread. *Eur. J. Clin. Microbiol. Infect. Dis.* 34, 773–778. doi: 10.1007/s10096-014-2291-8
- Heikkilä, M. P., and Saris, P. E. J. (2003). Inhibition of *Staphylococcus aureus* by the commensal bacteria of human milk. *J. Appl. Microbiol.* 95, 471–478. doi: 10.1046/j.1365-2672.2003.02002.x
- Himeno, K., Rosengren, K. J., Inoue, T., Perez, R. H., Colgrave, M. L., Lee, H. S., et al. (2015). Identification, characterization, and three-dimensional structure of the novel circular bacteriocin, enterocin NKR-5-3B, from *Enterococcus faecium*. *Biochemistry* 54, 4863–4876. doi: 10.1021/acs.biochem.5b00196
- Holmes, M. A., and Zadoks, R. N. (2011). Methicillin resistant *S. aureus* in human and bovine mastitis. *J. Mammary Gland. Biol. Neoplasia.* 16, 373–382. doi: 10.1007/s10911-011-9237-x
- Hunt, K. M., Foster, J. A., Forney, L. J., Schütte, U. M. E., Beck, D. L., Abdo, Z., et al. (2011). Characterization of the diversity and temporal stability of bacterial communities in human milk. *PLoS One* 6:e21313. doi: 10.1371/journal.pone.0021313
- Janek, D., Zipperer, A., Kulik, A., Krismer, B., and Peschel, A. (2016). High frequency and diversity of antimicrobial activities produced by nasal *Staphylococcus* strains against bacterial competitors. *PLoS Pathog.* 12:e1005812. doi: 10.1371/journal.ppat.1005812
- Jiménez, E., Fernandez, L., Maldonado, A., Martín, R., Olivares, M., Xaus, J., et al. (2008). Oral administration of *Lactobacillus* strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation. *Appl. Environ. Microbiol.* 74, 4650–4655. doi: 10.1128/AEM.02599-07
- Kjos, M., Nes, I. F., and Diep, D. B. (2009). Class II one-peptide bacteriocins target a phylogenetically defined subgroup of mannose phosphotransferase systems on sensitive cells. *Microbiology* 155, 2949–2961. doi: 10.1099/mic.0.030015-0
- Klostermann, K., Crispie, F., Flynn, J., Meaney, W. J., Ross, R. P., and Hill, C. (2009). Efficacy of a teat dip containing the bacteriocin lactacin 3147 to eliminate Gram-positive pathogens associated with bovine mastitis. *J. Dairy Res.* 77, 231–238. doi: 10.1017/S0022029909990239
- Kohira, N., West, J., Ito, A., Ito-Horiyama, T., Nakamura, R., Sato, T., et al. (2016). *In vitro* antimicrobial activity of a siderophore cephalosporin, S-649266, against *enterobacteriaceae* clinical isolates, including carbapenem-resistant strains. *Antimicrob. Agents Chemother.* 60, 729–734. doi: 10.1128/AAC.01695-15
- Kort, R., Caspers, M., van de Graaf, A., van Egmond, W., Keijser, B., and Roeselers, G. (2014). Shaping the oral microbiota through intimate kissing. *Microbiome* 2:41. doi: 10.1186/2049-2618-2-41
- Kotelnikova, E. A., and Gelfand, M. S. (2002). Bacteriocin production by gram-positive bacteria and the mechanisms of transcriptional regulation. *Russ. J. Genet.* 38, 628–641. doi: 10.1023/A:1016035700012
- Li, R., Fein, S. B., Chen, J., and Grummer-Strawn, L. M. (2008). Why mothers stop breastfeeding: mothers' self-reported reasons for stopping during the first year. *Pediatrics* 122, S69–S76. doi: 10.1542/peds.2008-1315I
- Li, Y., Li, Y., Li, Q., Gao, J., Wang, J., Luo, Y., et al. (2018). Biosynthetic and antimicrobial potential of actinobacteria isolated from bulrush rhizospheres habitat in Zhalong Wetland. *China. Arch. Microbiol.* 200, 695–705. doi: 10.1007/s00203-018-1474-6
- Lu, H., Giordano, F., and Ning, Z. (2016). Oxford nanopore MinION sequencing and genome assembly. *Genomics Proteomics Bioinformatics* 14, 265–279. doi: 10.1016/j.gpb.2016.05.004
- Lubelski, J., Rink, R., Khusainov, R., Moll, G. N., and Kuipers, O. P. (2008). Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. *Cell Mol. Life. Sci.* 65, 455–476. doi: 10.1007/s00018-007-7171-2

- Madsen, K. T., Skov, M. N., Gill, S., and Kemp, M. (2017). Virulence factors associated with *Enterococcus faecalis* infective endocarditis: a mini review. *Open Microbiol J.* 11, 1–11. doi: 10.2174/1874285801711010001
- Maldonado-Barragan, A., Caballero-Guerrero, B., Lucena-Padros, H., and Ruiz-Barba, J. L. (2013). Induction of bacteriocin production by coculture is widespread among plantaricin-producing *Lactobacillus plantarum* strains with different regulatory operons. *Food Microbiol.* 33, 40–47. doi: 10.1016/j.fm.2012.08.009
- Marsh, A. J., O'Sullivan, O., Ross, R. P., Cotter, P. D., and Hill, C. (2010). *In silico* analysis highlights the frequency and diversity of type I lantibiotic gene clusters in genome sequenced bacteria. *BMC Genomics* 11:679. doi: 10.1186/1471-2164-11-679
- Martin, C. R., Ling, P.-R., and Blackburn, G. L. (2016). Review of infant feeding: key features of breast milk and infant formula. *Nutrients.* 8:279. doi: 10.3390/nu8050279
- Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet J.* 17, 10–12. doi: 10.14806/ej.17.1.200
- Martínez, B., Fernández, M., Suárez, E. J., and Rodríguez, A. (1999). Synthesis of lactococcin 972, a bacteriocin produced by *Lactococcus lactis* IPLA 972, depends on the expression of a plasmid-encoded bicistronic operon. *Microbiology* 145, 3155–3161. doi: 10.1099/00221287-145-11-3155
- Martínez, B., Rodríguez, A., and Suárez, J. E. (2000). Lactococcin 972, a bacteriocin that inhibits septum formation in lactococci. *Microbiology* 146, 949–955. doi: 10.1099/00221287-146-4-949
- Martin-Visscher, L. A., van Belkum, M. J., and Vederas, J. C. (2011). “Class IIc or circular bacteriocins,” in *Prokaryotic Antimicrobial Peptides: From Genes to Applications*, eds D. Drider and S. Rebuffat (New York, NY: Springer), 213–236. doi: 10.1007/978-1-4419-7692-5_12
- Mathur, H., Rea, M. C., Cotter, P. D., Hill, C., and Ross, R. P. (2015). The sactibiotic subclass of bacteriocins: an update. *Curr. Protein Pept. Sci.* 16, 549–558. doi: 10.2174/1389203716666150515124831
- McAuliffe, O., Hill, C., and Ross, R. P. (2000). Each peptide of the two-component lantibiotic lactacin 3147 requires a separate modification enzyme for activity. *Microbiology* 146, 2147–2154. doi: 10.1099/00221287-146-9-2147
- Mediano, P., Fernández, L., Jiménez, E., Arroyo, R., Espinosa-Martos, I., Rodríguez, J. M., et al. (2017). Microbial diversity in milk of women with mastitis: potential role of coagulase-negative staphylococci, viridans group streptococci, and corynebacteria. *J. Hum. Lact.* 33, 309–318. doi: 10.1177/0890334417692968
- Moll, G., Ubink-Kok, T., Hildeng-Hauge, H., Nissen-Meyer, J., Nes, I. F., Konings, W. N., et al. (1996). Lactococcin G is a potassium ion-conducting, two-component bacteriocin. *J. Bacteriol.* 178:600. doi: 10.1128/jb.178.3.600-605.1996
- Murphy, E. F., Cotter, P. D., Hogan, A., O'Sullivan, O., Joyce, A., Fouhy, F., et al. (2013). Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. *Gut.* 62, 220–226. doi: 10.1136/gutjnl-2011-300705
- Nikaido, H. (2003). Molecular basis of bacterial outer membrane permeability revisited. *Microbiol. Mol. Biol. Rev.* 67, 593–656. doi: 10.1128/mmbr.67.4.593-656.2003
- Nikaido, H., and Vaara, M. (1985). Molecular basis of bacterial outer membrane permeability. *Microbiol. Rev.* 49, 1–32. doi: 10.1128/mmbr.49.1.1-32.1985
- Nissen-Meyer, J., Opegård, C., Rogne, P., Haugen, H. S., and Kristiansen, P. E. (2010). Structure and mode-of-action of the two-peptide (class-IIb) bacteriocins. *Probiotics Antimicrob. Proteins.* 2, 52–60. doi: 10.1007/s12602-009-9021-z
- Nurk, S., Meleshko, D., Korobeynikov, A., and Pevzner, P. A. (2017). metaSPAdes: a new versatile metagenomic assembler. *Genome Res.* 27, 824–834. doi: 10.1101/gr.213959
- O'Sullivan, J. N., Rea, M. C., O'Connor, P. M., Hill, C., and Ross, R. P. (2019). Human skin microbiota is a rich source of bacteriocin-producing staphylococci that kill human pathogens. *FEMS Microbiol. Ecol.* 95:fy241. doi: 10.1093/femsec/fy241
- Overbeek, R., Olson, R., Pusch, G. D., Olsen, G. J., Davis, J. J., Disz, T., et al. (2014). The SEED and the rapid annotation of microbial genomes using subsystems technology (RAST). *Nucleic Acids Res.* 42, D206–D214. doi: 10.1093/nar/gkt1226
- Padilha, M., Danneskiold-Samsoe, N. B., Brejnrod, A., Hoffmann, C., Cabral, V. P., Iaucci, J. M., et al. (2019). The human milk microbiota is modulated by maternal diet. *Microorganisms* 7, 502. doi: 10.3390/microorganisms7110502
- Paviour, S., Musaad, S., Roberts, S., Taylor, G., Taylor, S., Shore, K., et al. (2002). *Corynebacterium* species isolated from patients with mastitis. *Clin. Infect. Dis.* 35, 1434–1440. doi: 10.1086/344463
- Perez, P. F., Doré, J., Leclerc, M., Levenez, F., Benyacoub, J., Serrant, P., et al. (2007). Bacterial imprinting of the neonatal immune system: lessons from maternal cells? *Pediatrics* 119:e724. doi: 10.1542/peds.2006-1649
- Perez, R. H., Zendo, T., and Sonomoto, K. (2018). Circular and leaderless bacteriocins: biosynthesis, mode of action, applications, and prospects. *Front. Microbiol.* 9:2085. doi: 10.3389/fmicb.2018.02085
- Rea, M. C., Sit, C. S., Clayton, E., Connor, P. M., Whittall, R. M., Zheng, J., et al. (2010). Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against *Clostridium difficile*. *Proc. Natl. Acad. Sci. U.S.A.* 107, 9352–9357. doi: 10.1073/pnas.0913554107
- Rhoads, A., and Au, K. F. (2015). PacBio sequencing and its applications. *Genom. Proteom. Bioin.* 13, 278–289. doi: 10.1016/j.gpb.2015.08.002
- Ross, A. A., Doxey, A. C., and Neufeld, J. D. (2017). The skin microbiome of cohabiting couples. *mSystems* 2:e043-17. doi: 10.1128/mSystems.00043-17
- Shah, M. M., Iihara, H., Noda, M., Song, S. X., Nhung, P. H., Ohkusu, K., et al. (2007). dnaJ gene sequence-based assay for species identification and phylogenetic grouping in the genus *Staphylococcus*. *Int. J. Syst. Evol. Microbiol.* 57, 25–30. doi: 10.1099/ijs.0.64205-0
- van Heel, A. J., de Jong, A., Montalban-Lopez, M., Kok, J., and Kuipers, O. P. (2013). BAGEL3: Automated identification of genes encoding bacteriocins and (non-)bacteriocidal posttranslationally modified peptides. *Nucleic Acids Res.* 41, W448–W453. doi: 10.1093/nar/gkt391
- Velásquez, J. E., Zhang, X., and van der Donk, W. A. (2011). Biosynthesis of the antimicrobial peptide epilancin 15X and its N-terminal lactate. *Chem. Biol.* 18, 857–867. doi: 10.1016/j.chembiol.2011.05.007
- Waterhouse, A. M., Procter, J. B., Martin, D. M., Clamp, M., and Barton, G. J. (2009). Jalview Version 2—a multiple sequence alignment editor and analysis workbench. *Bioinformatics* 25, 1189–1191. doi: 10.1093/bioinformatics/bt033
- Wayah, S. B., and Philip, K. (2018). Pentocin MQ1: a novel, broad-spectrum, pore-forming bacteriocin from *Lactobacillus pentosus* CS2 with quorum sensing regulatory mechanism and biopreservative potential. *Front. Microbiol.* 9:564. doi: 10.3389/fmicb.2018.00564
- WHO (2000). *Mastitis: Causes and Management*. Geneva: World Health Organization, 1–45.
- Wong, S. C. Y., Poon, R. W. S., Chen, J. H. K., Tse, H., Lo, J. Y. C., Ng, T. K., et al. (2017). *Corynebacterium kroppenstedtii* is an emerging cause of mastitis especially in patients with psychiatric illness on antipsychotic medication. *Open Forum Infect. Dis.* 4:ofx096. doi: 10.1093/ofid/ofx096
- Zengin, H., and Baysal, A. H. (2014). Antibacterial and antioxidant activity of essential oil terpenes against pathogenic and spoilage-forming bacteria and cell structure-activity relationships evaluated by SEM microscopy. *Molecules* 19, 17773–17798. doi: 10.3390/molecules191117773
- Zhang, J., Du, L., Liu, F., Xu, F., Hu, B., Venturi, V., et al. (2014). Involvement of both PKS and NRPS in antibacterial activity in *Lysobacter enzymogenes* OH11. *FEMS Microbiol. Lett.* 355, 170–176. doi: 10.1111/1574-6968.12457
- Zipperer, A., Konnerth, M. C., Laux, C., Berscheid, A., Janek, D., Weidenmaier, C., et al. (2016). Human commensals producing a novel antibiotic impair pathogen colonization. *Nature* 535, 511–516. doi: 10.1038/nature18634

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Angelopoulou, Warda, O'Connor, Stockdale, Shkoporov, Field, Draper, Stanton, Hill and Ross. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.